Gastroesophageal Junction Adenocarcinoma

Oncology·MeSH: Esophageal Neoplasms

13 drugs in development·6 companies·23 clinical trials

Drug Pipeline by Phase

Approved(4)

Phase 2(3)

Drug	Company
Chemotherapeutic Agent	Merus N.V. (MRUS)
increase dose of tocilizumab	Merus N.V. (MRUS)
utidelone	BIOSTAR PHARMACEUTICALS, INC. (BSPM)

Phase 1(4)

Phase 2/Phase 3(2)

Drug	Company
fluoropyrimidine-	BIOSTAR PHARMACEUTICALS, INC. (BSPM)
pd-1 inhibitor	BIOSTAR PHARMACEUTICALS, INC. (BSPM)

BioSniper tracks 13 drugs in development for Gastroesophageal Junction Adenocarcinoma across 6 companies.

There are 23 clinical trials targeting Gastroesophageal Junction Adenocarcinoma tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.